Meeting
2023 ASCO Gastrointestinal Cancers Symposium
CTX-009 (ABL001), a bispecific antibody targeting DLL4 and VEGF A, in combination with paclitaxel in patients with advanced biliary tract cancer (BTC): A phase 2 study.
Authors
Do-Youn Oh
Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea, Republic of (South);
Do-Youn Oh , Joon Oh Park , Jin Won Kim , Kyu-Pyo Kim , Jeesun Yoon , Tae-Yong Kim , Seung Tae Kim , Young Suk Park , Jeeyun Lee , Ji-Won Kim , Keun-Wook Lee , Baek-Yeol Ryoo , Changhoon Yoo , BokJin Hyun , HyunJoo Son , SunYoung Kim , SangMi Lee , Jooyeon Park , Eunsin Ha
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04492033
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 540)
DOI
10.1200/JCO.2023.41.4_suppl.540
Abstract #
540
Poster Bd #
C10
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.
First Author: Zev A. Wainberg
Poster
2018 ASCO Annual Meeting
ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.
First Author: Zev A. Wainberg
Poster
2017 Gastrointestinal Cancers Symposium
A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer.
First Author: Naminatsu Takahara
Poster
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
First Author: John Ebben